| Health disinformation use case highlighting the urgent need for artificial intelligence vigilance: weapons of mass disinformation BD Menz, ND Modi, MJ Sorich, AM Hopkins JAMA internal medicine 184 (1), 92-96, 2024 | 28 | 2024 |
| Patient‐reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy AM Hopkins, J Wagner, G Kichenadasse, N Modi, A Rowland, MJ Sorich International Journal of Cancer 147 (11), 3085-3089, 2020 | 25 | 2020 |
| The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data ND Modi, JQE Tan, A Rowland, B Koczwara, AY Abuhelwa, ... NPJ Breast Cancer 7 (1), 30, 2021 | 24 | 2021 |
| Design, synthesis and evaluation of a series of 5-methoxy-2, 3-naphthalimide derivatives as AcrB inhibitors for the reversal of bacterial resistance C Jin, R Alenazy, Y Wang, R Mowla, Y Qin, JQE Tan, ND Modi, X Gu, ... Bioorganic & Medicinal Chemistry Letters 29 (7), 882-889, 2019 | 16 | 2019 |
| Predicting thrombocytopenia in patients with breast cancer treated with ado-trastuzumab emtansine ND Modi, MJ Sorich, A Rowland, RA McKinnon, B Koczwara, MD Wiese, ... Clinical Breast Cancer 20 (2), e220-e228, 2020 | 15 | 2020 |
| Audit of data sharing by pharmaceutical companies for anticancer medicines approved by the US Food and Drug Administration ND Modi, AY Abuhelwa, RA McKinnon, AV Boddy, M Haseloff, MD Wiese, ... JAMA oncology 8 (9), 1310-1316, 2022 | 14 | 2022 |
| Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib ND Modi, AY Abuhelwa, S Badaoui, E Shaw, K Shankaran, RA McKinnon, ... The Breast 58, 57-62, 2021 | 12 | 2021 |
| The influence of pre-existing beta-blockers use on survival outcomes in HER2 positive advanced breast cancer: pooled analysis of clinical trial data ND Modi, JQE Tan, A Rowland, B Koczwara, G Kichenadasse, ... Frontiers in Oncology 10, 1130, 2020 | 11 | 2020 |
| A literature review of treatment-specific clinical prediction models in patients with breast cancer ND Modi, MJ Sorich, A Rowland, JM Logan, RA McKinnon, ... Critical Reviews in Oncology/Hematology 148, 102908, 2020 | 11 | 2020 |
| Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer ND Modi, NO Danell, RNA Perry, AY Abuhelwa, A Rathod, S Badaoui, ... ESMO open 7 (3), 100475, 2022 | 9 | 2022 |
| Current safeguards, risk mitigation, and transparency measures of large language models against the generation of health disinformation: repeated cross sectional analysis BD Menz, NM Kuderer, S Bacchi, ND Modi, B Chin-Yee, T Hu, C Rickard, ... bmj 384, 2024 | 8 | 2024 |
| A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies ND Modi, G Kichenadasse, TC Hoffmann, M Haseloff, JM Logan, ... BMC medicine 21 (1), 400, 2023 | 8 | 2023 |
| Heterogeneity and utility of pharmaceutical company sharing of individual-participant data packages AM Hopkins, ND Modi, AY Abuhelwa, G Kichenadasse, NM Kuderer, ... JAMA oncology 9 (12), 1621-1626, 2023 | 7 | 2023 |
| The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data. NPJ Breast Cancer 7: 30 ND Modi, JQE Tan, A Rowland, B Koczwara, AY Abuhelwa, ... | 5 | 2021 |
| Early adverse events predict survival outcomes in HER2-positive advanced breast cancer patients treated with lapatinib plus capecitabine FLI Ang, A Rowland, ND Modi, RA McKinnon, MJ Sorich, AM Hopkins Journal of Cancer 11 (11), 3327, 2020 | 4 | 2020 |
| Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation AM Hopkins, ND Modi, FW Rockhold, T Hoffmann, BD Menz, AA Veroniki, ... Journal of Clinical Epidemiology 167, 111263, 2024 | 2 | 2024 |
| Association between patient-reported outcomes and survival in patients with advanced urothelial carcinoma treated with atezolizumab E Tan, AY Abuhelwa, S Badaoui, ND Modi, MD Wiese, RA McKinnon, ... Bladder Cancer 8 (1), 81-88, 2022 | 2 | 2022 |
| Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability. ND Modi, SM Swain, M Buyse, NM Kuderer, A Rowland, FW Rockhold, ... Journal of Clinical Oncology: Official Journal of the American Society of …, 2024 | | 2024 |
| Special Paper: Current safeguards, risk mitigation, and transparency measures of large language models against the generation of health disinformation: repeated cross sectional … BD Menz, NM Kuderer, S Bacchi, ND Modi, B Chin-Yee, T Hu, C Rickard, ... The BMJ 384, 2024 | | 2024 |
| Is there a harmonised standard to oncology trial data provision in data sharing initiatives? AM Hopkins, N Modi, MJ Sorich Journal of Clinical Oncology 41 (16_suppl), e13645-e13645, 2023 | | 2023 |
Michael SorichProfessor of Clinical Pharmacology, Flinders University在 flinders.edu.au 的电子邮件经过验证
